Literature DB >> 18604772

[Reasons for underuse of oral anticoagulation in atrial fibrillation-associated stroke: prospective study of German stroke patients].

B Reicke1, F Masuhr, M Weih.   

Abstract

Oral anticoagulation in atrial fibrillation (AF) is effective in primary and secondary prevention of cardioembolic stroke, but is often underused in practice. The detailed reasons for non-use of oral anticoagulation are less well known. We prospectively analyzed 105 consecutive cases of acute ischemic stroke associated with atrial fibrillation. Patients were investigated by a semi-structured interview. The most frequent reasons for underuse were: unknown AF (43 %). In case of known AF: reluctance of patients (30 %), contraindications (25 %) and compliance problems (20 %). There was good agreement between patients and physicians views about nonuse or aborted use of oral anticoagulation (kappa 0.64 and 0.93, respectively). Unknown atrial fibrillation is the most prevalent cause of underutilization of oral anticoagulation in acute stroke patients. Since atrial fibrillation is easy to detect in most cases, it could be worthwhile to screen elderly patients without contraindications for anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604772     DOI: 10.1055/s-2008-1038216

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  2 in total

1.  [Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice].

Authors:  A Osterspey; A Krome
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

Review 2.  Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study.

Authors:  Linda R Tulner; Jos P C M Van Campen; Ingeborg M J A Kuper; George J P T Gijsen; Cornelis H W Koks; Melvin R Mac Gillavry; Harm van Tinteren; Jos H Beijnen; Desiderius P M Brandjes
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.